Revelation Biosciences (REVB) Competitors

Revelation Biosciences logo
$4.24 -0.14 (-3.20%)
As of 11:55 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

REVB vs. MBIO, SLRX, THAR, ARTL, OGEN, MAAQ, ALBT, PTIX, CPHI, and SNOA

Should you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Mustang Bio (MBIO), Salarius Pharmaceuticals (SLRX), Tharimmune (THAR), Artelo Biosciences (ARTL), Oragenics (OGEN), Mana Capital Acquisition (MAAQ), Avalon GloboCare (ALBT), Protagenic Therapeutics (PTIX), China Pharma (CPHI), and Sonoma Pharmaceuticals (SNOA). These companies are all part of the "pharmaceutical products" industry.

Revelation Biosciences vs.

Revelation Biosciences (NASDAQ:REVB) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Revelation Biosciences and Revelation Biosciences both had 1 articles in the media. Mustang Bio's average media sentiment score of 1.10 beat Revelation Biosciences' score of 1.00 indicating that Mustang Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Revelation Biosciences Positive
Mustang Bio Positive

Revelation Biosciences has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.

Mustang Bio received 139 more outperform votes than Revelation Biosciences when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 63.83% of users gave Revelation Biosciences an outperform vote.

CompanyUnderperformOutperform
Revelation BiosciencesOutperform Votes
30
63.83%
Underperform Votes
17
36.17%
Mustang BioOutperform Votes
169
64.26%
Underperform Votes
94
35.74%

Mustang Bio's return on equity of 0.00% beat Revelation Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Revelation BiosciencesN/A -193.51% -84.00%
Mustang Bio N/A N/A -172.89%

Mustang Bio has a consensus target price of $100.00, indicating a potential upside of 3,222.26%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts plainly believe Mustang Bio is more favorable than Revelation Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revelation Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Mustang Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Mustang Bio is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revelation BiosciencesN/AN/A-$120K-$268.16-0.02
Mustang BioN/AN/A-$51.60M-$78.00-0.04

12.8% of Revelation Biosciences shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 0.1% of Revelation Biosciences shares are owned by insiders. Comparatively, 0.5% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Mustang Bio beats Revelation Biosciences on 10 of the 14 factors compared between the two stocks.

Get Revelation Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

REVB vs. The Competition

MetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.18M$7.00B$5.76B$9.08B
Dividend YieldN/A2.89%5.29%4.00%
P/E Ratio-0.0210.2388.5618.43
Price / SalesN/A241.85954.0768.32
Price / CashN/A22.6637.4433.55
Price / Book0.015.375.164.80
Net Income-$120,000.00$125.94M$109.04M$223.10M
7 Day Performance14.66%7.45%2.96%1.35%
1 Month Performance-57.43%4.74%2.95%-0.60%
1 Year Performance-89.47%10.82%26.01%23.28%

Revelation Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
REVB
Revelation Biosciences
1.2872 of 5 stars
$4.24
-3.2%
N/A-91.4%$1.15MN/A-0.0210Positive News
MBIO
Mustang Bio
3.0852 of 5 stars
$4.16
-13.2%
$100.00
+2,303.8%
-95.4%$3.99MN/A-0.05100Gap Down
SLRX
Salarius Pharmaceuticals
0.1907 of 5 stars
$2.46
-4.7%
N/A-50.9%$3.89MN/A-0.3020
THAR
Tharimmune
3.1135 of 5 stars
$2.01
-2.9%
$17.00
+745.8%
-67.5%$3.88MN/A0.002
ARTL
Artelo Biosciences
3.0233 of 5 stars
$1.20
+1.7%
$5.50
+358.3%
+0.0%$3.88MN/A-0.425Gap Down
OGEN
Oragenics
N/A$0.31
+0.3%
N/AN/A$3.76M$40,000.00-0.045News Coverage
Gap Down
MAAQ
Mana Capital Acquisition
N/A$0.46
-8.1%
N/A-92.7%$3.73MN/A0.001High Trading Volume
ALBT
Avalon GloboCare
0.6621 of 5 stars
$3.39
-5.3%
N/A-45.2%$3.70M$1.26M-0.175
PTIX
Protagenic Therapeutics
1.5729 of 5 stars
$0.51
+14.0%
N/A-61.0%$3.67MN/A-0.402Gap Down
High Trading Volume
CPHI
China Pharma
N/A$0.19
-7.4%
N/A-54.5%$3.62M$7.01M0.00250
SNOA
Sonoma Pharmaceuticals
0.8408 of 5 stars
$2.64
-7.0%
N/A+1,581.4%$3.54M$12.73M-0.53180Earnings Report
Upcoming Earnings
News Coverage

Related Companies and Tools


This page (NASDAQ:REVB) was last updated on 2/6/2025 by MarketBeat.com Staff
From Our Partners